CN1230441C - 结合整联蛋白的肽衍生物 - Google Patents

结合整联蛋白的肽衍生物 Download PDF

Info

Publication number
CN1230441C
CN1230441C CNB018109411A CN01810941A CN1230441C CN 1230441 C CN1230441 C CN 1230441C CN B018109411 A CNB018109411 A CN B018109411A CN 01810941 A CN01810941 A CN 01810941A CN 1230441 C CN1230441 C CN 1230441C
Authority
CN
China
Prior art keywords
compound
amino
represent
acid residue
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018109411A
Other languages
English (en)
Chinese (zh)
Other versions
CN1436195A (zh
Inventor
A·库斯伯特森
B·因德雷沃尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
ANCHEN PHARMACEUTICALS AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0009042A external-priority patent/GB0009042D0/en
Priority claimed from GB0025070A external-priority patent/GB0025070D0/en
Application filed by ANCHEN PHARMACEUTICALS AS filed Critical ANCHEN PHARMACEUTICALS AS
Publication of CN1436195A publication Critical patent/CN1436195A/zh
Application granted granted Critical
Publication of CN1230441C publication Critical patent/CN1230441C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB018109411A 2000-04-12 2001-04-06 结合整联蛋白的肽衍生物 Expired - Lifetime CN1230441C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0009042.3 2000-04-12
GB0009042A GB0009042D0 (en) 2000-04-12 2000-04-12 Contrast agents
GB0025070A GB0025070D0 (en) 2000-10-12 2000-10-12 Contrast agents
GB0025070.4 2000-10-12

Publications (2)

Publication Number Publication Date
CN1436195A CN1436195A (zh) 2003-08-13
CN1230441C true CN1230441C (zh) 2005-12-07

Family

ID=26244091

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018109411A Expired - Lifetime CN1230441C (zh) 2000-04-12 2001-04-06 结合整联蛋白的肽衍生物

Country Status (16)

Country Link
US (2) US7351790B2 (enExample)
EP (1) EP1272507B1 (enExample)
JP (1) JP5043271B2 (enExample)
KR (2) KR100879702B1 (enExample)
CN (1) CN1230441C (enExample)
AT (1) ATE298763T1 (enExample)
AU (2) AU2001250683B2 (enExample)
CA (1) CA2405469C (enExample)
DE (1) DE60111733T2 (enExample)
DK (1) DK1272507T3 (enExample)
ES (1) ES2244607T3 (enExample)
HK (1) HK1052711A1 (enExample)
NO (1) NO331741B1 (enExample)
NZ (1) NZ521735A (enExample)
PT (1) PT1272507E (enExample)
WO (1) WO2001077145A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
NZ521735A (en) * 2000-04-12 2004-12-24 Amersham Health As Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
JP4510444B2 (ja) * 2001-07-10 2010-07-21 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
EP1575496A4 (en) * 2002-04-05 2008-01-23 Univ Utah Res Found COLON TUMOR SPECIFIC BINDING PEPTIDES
CN100491395C (zh) * 2002-04-11 2009-05-27 阿斯比奥制药株式会社 修饰肽的制造方法
GB0224799D0 (en) * 2002-10-25 2002-12-04 Amersham Plc Improved complex compositions
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
NO20033115D0 (no) 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
JP2007526300A (ja) 2004-03-04 2007-09-13 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
CN1968963A (zh) * 2004-06-16 2007-05-23 通用电气医疗集团股份有限公司 基于肽的化合物
JP5280682B2 (ja) * 2004-06-16 2013-09-04 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物
EP1765172B1 (en) * 2004-06-18 2013-04-24 Elmaleh, David R. Intravascular imaging device and uses thereof
RU2007118385A (ru) * 2004-11-22 2008-12-27 Джи-И Хелткер АС (NO) Контрастные агенты для направлений доставки во внеклеточный матрикс
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
WO2006073314A1 (en) * 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
CA2625196C (fr) 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
JP2010502585A (ja) * 2006-08-28 2010-01-28 ジーイー・ヘルスケア・リミテッド ６８Ｇａ標識ペプチド系放射性医薬品
CN102321154A (zh) * 2006-12-11 2012-01-18 通用电气医疗集团股份有限公司 基于放射性标记的肽的化合物及其用途
US20090004119A1 (en) * 2007-06-27 2009-01-01 Ge Healthcare As Polymers
DE102007036570A1 (de) 2007-08-03 2009-02-19 Siemens Ag Screeningtest zur Erkennung von Prostataerkrankungen sowie Vorrichtung und Diagnosesubstanz zur Durchführung des Tests
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
EP3365353B1 (en) * 2015-10-23 2023-11-22 Universiteit Twente Integrin binding peptides and uses thereof
WO2019040367A1 (en) * 2017-08-19 2019-02-28 Ohio State Innovation Foundation NEW CANCER IMAGING AGENTS BASED ON PEPTIDES
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
EP3970801A4 (en) * 2019-05-14 2022-11-02 Ichimaru Pharcos Co., Ltd. RAS INHIBITOR PEPTIDE

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
DE3869251D1 (de) 1987-07-16 1992-04-23 Nycomed As Aminopolycarbonsaeure und ihre derivate.
US5753627A (en) * 1988-12-05 1998-05-19 Novartis Ag Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
IE901736L (en) 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
UA43823C2 (uk) 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
IL113139A0 (en) 1994-03-28 1995-06-29 Nycomed Imaging As Diagnostic compositions comprising imaging agents encapsulated in liposomes
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
GB9420390D0 (en) 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
AU726793B2 (en) 1995-08-14 2000-11-23 Scripps Research Institute, The Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis
ES2299232T3 (es) 1995-09-11 2008-05-16 La Jolla Cancer Research Foundation Moleculas que migran hacia un organo o tejido seleccionado in vivo.
JP4280304B2 (ja) 1996-01-10 2009-06-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
WO1997028830A1 (de) 1996-02-09 1997-08-14 Steinel Gmbh & Co. Kg Vorrichtung zum verdunsten eines flüssigen wirkstoffes
JP2001501600A (ja) 1996-09-10 2001-02-06 ザ バーナム インスティテュート 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
CA2291323A1 (en) 1997-05-28 1998-12-03 Genvec, Inc. Alternatively targeted adenovirus
GB9711115D0 (en) 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
EP1053013A4 (en) 1998-02-06 2004-12-22 Uab Research Foundation ADENOVIRUS VECTOR CONTAINING A HETEROLOGICAL PEPTIDEPITOP IN THE HI LOOP OF THE FIBER BUTTON
AU2662999A (en) 1998-02-09 1999-08-23 Genzyme Corporation Nucleic acid delivery vehicles
NZ521735A (en) * 2000-04-12 2004-12-24 Amersham Health As Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser

Also Published As

Publication number Publication date
AU5068301A (en) 2001-10-23
ATE298763T1 (de) 2005-07-15
US7351790B2 (en) 2008-04-01
AU2001250683B2 (en) 2006-06-29
EP1272507B1 (en) 2005-06-29
DK1272507T3 (da) 2005-10-03
NO20024932D0 (no) 2002-10-14
KR20080036662A (ko) 2008-04-28
CA2405469A1 (en) 2001-10-18
NZ521735A (en) 2004-12-24
CA2405469C (en) 2012-03-20
KR100866666B1 (ko) 2008-11-04
US8404802B2 (en) 2013-03-26
DE60111733T2 (de) 2006-05-18
DE60111733D1 (de) 2005-08-04
HK1052711A1 (zh) 2003-09-26
JP5043271B2 (ja) 2012-10-10
KR20020087973A (ko) 2002-11-23
NO331741B1 (no) 2012-03-19
US20080187493A1 (en) 2008-08-07
EP1272507A2 (en) 2003-01-08
PT1272507E (pt) 2005-11-30
WO2001077145A3 (en) 2002-05-10
ES2244607T3 (es) 2005-12-16
KR100879702B1 (ko) 2009-01-21
US20030204049A1 (en) 2003-10-30
WO2001077145A2 (en) 2001-10-18
CN1436195A (zh) 2003-08-13
JP2003531835A (ja) 2003-10-28

Similar Documents

Publication Publication Date Title
CN1230441C (zh) 结合整联蛋白的肽衍生物
CN1622830A (zh) 肽基化合物
CN1087631C (zh) 用于诊断和治疗的放射性标记肽
CN1295578A (zh) 用于血管生成性疾病成像的药物
CN1527727A (zh) 改进的螯合剂共轭物
CN1829735A (zh) 显象剂
CN1599577A (zh) 肽基多聚体靶向的造影介质
CN1462276A (zh) 肽基化合物
CN1738650A (zh) 改进的胃泌素释放肽化合物
CN1074911A (zh) 将生物作用的物质结合至生物粒子面膜上的化合物，组合物和方法
CN1968963A (zh) 基于肽的化合物
CN1158090A (zh) 含单胺、联氨、硫羟基的金属螯合剂
CN1149588A (zh) 环化粘合抑制剂
CN1192733A (zh) 制备放射性药物的稳定试剂
CN1122577A (zh) 放射标记的血小板GPIIb/IIIa受体拮抗剂作为诊断血栓栓塞疾病的成象剂
CN1119351C (zh) 环状粘着抑制剂
CN1738652A (zh) 用于药物化合物的改进的接头
CN101065152A (zh) 靶向尿激酶纤溶酶原激活物受体的造影剂
JP7221937B2 (ja) 腫瘍標的化ペプチドバリアント
CN1820025A (zh) 荧光素标记的肽
CN1901941A (zh) 血管紧张素ii与成像部分的缀合物
CN101039702A (zh) 作为靶向试剂用于内皮－特异性体内转导的热激蛋白
HK1107102A (en) Peptide-based compounds
CN1741809A (zh) 靶向肿瘤和内皮细胞的肽,其组合物和用途
HK1036458A (en) Pharmaceuticals for the imaging of angiogenic disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: GE HEALTHCARE AS

Free format text: FORMER NAME OR ADDRESS: ANCHEN PHARMACEUTICALS AS

CP01 Change in the name or title of a patent holder

Address after: Oslo, Norway

Patentee after: GE HEALTHCARE A/S

Address before: Oslo, Norway

Patentee before: AMERSHAM HEALTH A/S

TR01 Transfer of patent right

Effective date of registration: 20171228

Address after: Buckinghamshire

Patentee after: GE HEALTHCARE Ltd.

Address before: Oslo, Norway

Patentee before: GE HEALTHCARE A/S

TR01 Transfer of patent right
CX01 Expiry of patent term

Granted publication date: 20051207

CX01 Expiry of patent term